戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 hrenia based on NMDA-receptor blockade using subanesthetic administration of ketamine.
2                                              Subanesthetic, antidepressant-like doses of (S)-ketamine
3                                            A subanesthetic, but not anesthetic, dose of ketamine sign
4 ffects on hippocampal synaptic function at a subanesthetic, but therapeutically relevant concentratio
5 3 cells stably transfected with hL1, whereas subanesthetic concentrations of 3-azioctanol (14 microM)
6                                              Subanesthetic concentrations of 3-diazirinyloctanol enha
7             Effects of N(2)O and ketamine at subanesthetic concentrations were evaluated by acute adm
8 hat 1-octanol inhibited native T-currents at subanesthetic concentrations with an IC(50) of approxima
9                                           At subanesthetic concentrations, N(2)O blocks low-voltage-a
10 eurons and Ca(v)3.2 currents in HEK cells at subanesthetic concentrations.
11  in regional brain metabolism induced by the subanesthetic dose may be relevant to effects of ketamin
12                                    A single, subanesthetic dose of (R,S)-ketamine (ketamine) exerts r
13                               Ketamine, at a subanesthetic dose of 35 mg/kg, substantially increased
14                                            A subanesthetic dose of ketamine causes acute psychotomime
15            In the hippocampal formation, the subanesthetic dose of ketamine induced prominent increas
16 pressant and antisuicidal effect of a single subanesthetic dose of ketamine infusion for treatment-re
17                                     A single subanesthetic dose of ketamine normalized glutamate rece
18 ance imaging to investigate the effects of a subanesthetic dose of ketamine on measures of functional
19 transmission that is reversible by an acute, subanesthetic dose of ketamine, along with regionally se
20                                     A single subanesthetic dose of ketamine, an NMDA receptor (NMDAR)
21  A, n = 25) during intravenous infusion of a subanesthetic dose of ketamine, compared to normal salin
22 e been observed in nonhuman primates after a subanesthetic dose of ketamine, including an impairment
23 se in glutamine/glutamate ratios to a single subanesthetic dose of ketamine, which mirrors the time c
24  locus for the generation of HFO following a subanesthetic dose of ketamine.
25 cal sounds following the administration of a subanesthetic dose of ketamine.
26 ted increased 2-DG uptake in response to the subanesthetic dose of the drug.
27  widely replicated observation that a single subanesthetic dose of the N-methyl-D-aspartate glutamate
28 e observed in select brain regions after the subanesthetic dose, an anesthetic dose of ketamine (100
29 ast, ketamine, when administered as a single subanesthetic dose, exerts rapid and sustained antidepre
30 NMDA antagonist ketamine, when injected at a subanesthetic dose, produces working memory deficit and
31 atomically identical to that produced by the subanesthetic dose.
32 supports the use of-or further research with-subanesthetic-dose ketamine and its (S)-enantiomer esket
33 n, evidence of an antidepressant response to subanesthetic-dose ketamine has led to a collection of s
34  pharmacology and hypothesized mechanisms of subanesthetic-dose ketamine in clinical research; 2) des
35 tly administered relatively low and moderate subanesthetic doses (<1 mg/kg approximate human intraven
36 ects when administered intravenously (IV) at subanesthetic doses (0.5 mg/kg over 40 min).
37                           The discovery that subanesthetic doses of (R, S)-ketamine (ketamine) and (S
38 ntidepressant properties of a broad range of subanesthetic doses of IV ketamine among outpatients wit
39  the efficacy of the 0.5 mg/kg and 1.0 mg/kg subanesthetic doses of IV ketamine and no clear or consi
40  in healthy volunteers (N = 10) who received subanesthetic doses of ketamine and in a group of clinic
41                                              Subanesthetic doses of ketamine can be used as a rapid-a
42 nkeys before and after the administration of subanesthetic doses of ketamine during the performance o
43                                              Subanesthetic doses of ketamine have been shown to exace
44 esent investigation show that anesthetic and subanesthetic doses of ketamine have pronounced effects
45 nkeys before and after the administration of subanesthetic doses of ketamine in a rule-based working
46 s previously demonstrated, administration of subanesthetic doses of ketamine increased 2-DG uptake in
47                                              Subanesthetic doses of ketamine increased mPFC amino aci
48                  Research has suggested that subanesthetic doses of ketamine may work to improve coca
49 f dopamine D(1A) receptors in the effects of subanesthetic doses of ketamine on both behavioral respo
50                                              Subanesthetic doses of ketamine were repeatedly shown to
51                                              Subanesthetic doses of ketamine, a noncompetitive NMDA r
52 he antidepressant and anti-stress effects of subanesthetic doses of ketamine, an NMDA receptor antago
53 ate release, following the administration of subanesthetic doses of ketamine, are related to the drug
54                 In this paper, we found that subanesthetic doses of ketamine, similar to those used i
55 n sought to define brain regions affected by subanesthetic doses of ketamine, using high resolution a
56 e elevated broadband gamma power elicited by subanesthetic doses of ketamine.
57 HFO, 130-180 Hz) are robustly potentiated by subanesthetic doses of ketamine.
58 ntional antidepressants drugs, as well as by subanesthetic doses of ketamine.
59 uced simultaneously by the administration of subanesthetic doses of ketamine.
60                                              Subanesthetic doses of MK-801 and ketamine induced ident
61                                              Subanesthetic doses of N-methyl-d-aspartate (NMDA) recep
62                                              Subanesthetic doses of NMDA receptor antagonists induce
63 ional and neutral slides while under various subanesthetic doses of sevoflurane or placebo (no anesth
64                                 For example, subanesthetic doses of the N-methyl-D-aspartate receptor
65                  Accordingly, the effects of subanesthetic doses of the non-competitive NMDA antagoni
66                                           At subanesthetic doses, ketamine and some metabolites are a
67                 When acutely administered at subanesthetic doses, ketamine causes cognitive deficits
68                                           At subanesthetic doses, ketamine, an N-methyl-D-aspartate g
69  are few MEG/EEG studies examining the acute subanesthetic effects of ketamine infusion in man.
70                                          One subanesthetic infusion can alleviate symptoms within hou
71 t study, the authors tested whether a single subanesthetic infusion of ketamine administered to adult
72          Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently us
73 uthors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically signifi
74 lved an anaesthesiologist infusing a single, subanesthetic, intravenous dose, and required hospitaliz
75 for such disparate findings by administering subanesthetic ketamine (1-30 mg/kg, i.v.) or vehicle to
76 tudies have found that repeated or high-dose subanesthetic ketamine administration results in consist
77         Rapid-acting antidepressants such as subanesthetic ketamine and sleep deprivation therapy can
78                                              Subanesthetic ketamine demonstrated promising effects on
79                                              Subanesthetic ketamine doses have been shown to have rap
80                                              Subanesthetic ketamine evokes rapid and long-lasting ant
81 n = 25 human males) examining the effects of subanesthetic ketamine infusion.
82 egative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepres
83   This investigation examined the effects of subanesthetic ketamine infusions on motivation for quitt
84                                              Subanesthetic ketamine is currently used as a rapid-acti
85                                              Subanesthetic ketamine is increasingly used for the trea
86 rsially, that a component of the efficacy of subanesthetic ketamine may be opioid dependent.
87                         Acute treatment with subanesthetic ketamine, a non-competitive N-methyl-D-asp
88 cillatory activity are widely reported after subanesthetic ketamine, however their mechanisms of gene
89  alterations driven by the administration of subanesthetic ketamine.
90                                Additionally, subanesthetic low-dose ketamine decreases anxiety- and d
91                    Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the exp